Downregulation of Aging-Associated Gene SUCLG1 Marks the Aggressiveness of Liver Disease.

Desislava K Tsoneva, Alessandro Napoli, Mariya Teneva, Tommaso Mazza, Manlio Vinciguerra
Author Information
  1. Desislava K Tsoneva: Department of Medical Genetics, Medical University of Varna, 9002 Varna, Bulgaria. ORCID
  2. Alessandro Napoli: Bioinformatics Laboratory, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 S. Giovanni Rotondo, FG, Italy.
  3. Mariya Teneva: Department of Medical Genetics, Medical University of Varna, 9002 Varna, Bulgaria.
  4. Tommaso Mazza: Bioinformatics Laboratory, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 S. Giovanni Rotondo, FG, Italy. ORCID
  5. Manlio Vinciguerra: Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University of Varna, 9002 Varna, Bulgaria.

Abstract

INTRODUCTION: The most common liver disease is nonalcoholic fatty liver disease, characterized by an intrahepatic accumulation of lipids that most often accompanies obesity. Fatty liver can evolve, in the presence of oxidative stress and inflammation, into disabling and deadly liver diseases such as cirrhosis, hepatocellular carcinoma (HCC), and cholangiocarcinoma (CC). Old age seems to favor HCC and CC, in agreement with the inflammaging theory, according to which aging accrues inflammation. Cancer, in general, is an age-related disease, as incidence and mortality for most types of cancer increase with age. However, how molecular drivers in tumors differ or are mutated more frequently among patients of different ages remains scarcely investigated. A recent integrative analysis of the age-associated multi-omic landscape across cancers and healthy tissues demonstrated that age-related gene expression changes are linked to numerous biological processes. HCC and CC have among the lowest five-year survival estimates due to their aggressive progression.
MATERIALS AND METHODS: In this study, we extracted top gene candidates from the above-mentioned pan-analyses (i.e., B2M, C1qA, SUCLG1) and tested by qPCR their expression and their correlation with disease progression in 48 tissue samples covering liver disease stages (fatty liver, hepatitis, cirrhosis, HCC and CC) and normal tissues.
RESULTS: Here, we report a significant downregulation in the expression of the age-associated gene SUCLG1 during the progression of liver disease toward HCC and CC, which also associates with poor patient survival.
CONCLUSION: SUCGL1, a mitochondrial enzyme gene that catalyzes the conversion of succinyl CoA to succinate, might be therapeutically targeted for the development and progression of age-associated liver cancers with low survival rates.

Keywords

References

  1. FEBS Lett. 2010 Sep 10;584(17):3819-25 [PMID: 20493857]
  2. Nat Chem Biol. 2011 Jan;7(1):58-63 [PMID: 21151122]
  3. Int J Mol Sci. 2021 Jun 16;22(12): [PMID: 34208592]
  4. Cochrane Database Syst Rev. 2024 Jun 4;6:CD013731 [PMID: 38837373]
  5. Br J Cancer. 2022 Feb;126(2):219-227 [PMID: 34616011]
  6. JCI Insight. 2021 Nov 22;6(22): [PMID: 34609963]
  7. Annu Rev Physiol. 2013;75:685-705 [PMID: 23140366]
  8. Curr Oncol. 2023 Jul 10;30(7):6609-6622 [PMID: 37504345]
  9. Cancer Control. 2007 Jan;14(1):23-31 [PMID: 17242668]
  10. Mech Ageing Dev. 2024 Jun;219:111939 [PMID: 38744412]
  11. Aging Dis. 2022 Jul 11;13(4):1239-1251 [PMID: 35855331]
  12. Cell Rep. 2021 Nov 16;37(7):110005 [PMID: 34788626]
  13. J Cell Mol Med. 2022 Nov;26(22):5702-5712 [PMID: 36308411]
  14. Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80 [PMID: 27095655]
  15. Nat Rev Genet. 2018 Jun;19(6):371-384 [PMID: 29643443]
  16. Cancer Res. 2016 Feb 1;76(3):594-606 [PMID: 26772755]
  17. Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9): [PMID: 27194046]
  18. Cell. 2013 Jun 6;153(6):1194-217 [PMID: 23746838]
  19. Nat Commun. 2021 Apr 20;12(1):2345 [PMID: 33879792]
  20. Nature. 2007 Aug 16;448(7155):767-74 [PMID: 17700693]
  21. J Hepatol. 2019 Jan;70(1):151-171 [PMID: 30266282]
  22. J Cell Biol. 2018 Jan 2;217(1):79-92 [PMID: 29070608]
  23. Comput Struct Biotechnol J. 2023 Oct 07;21:5174-5185 [PMID: 37920816]
  24. N Engl J Med. 2019 Apr 11;380(15):1450-1462 [PMID: 30970190]
  25. Hepatology. 2013 Aug;58(2):830-1 [PMID: 23281079]
  26. Trends Cancer. 2022 Nov;8(11):962-971 [PMID: 35811230]
  27. Aging (Albany NY). 2021 Feb 11;13(3):3313-3341 [PMID: 33611312]
  28. Ann Hepatol. 2024 Sep 12;30(2):101580 [PMID: 39276981]
  29. Cancer Cell Int. 2020 Jul 21;20:331 [PMID: 32699530]
  30. Mol Oncol. 2022 Sep;16(18):3295-3318 [PMID: 35666002]
  31. J Neuroinflammation. 2024 Nov 14;21(1):296 [PMID: 39543710]
  32. Cell Rep. 2021 Dec 7;37(10):110100 [PMID: 34879281]
  33. Front Med (Lausanne). 2020 Apr 03;7:113 [PMID: 32318579]
  34. Cell Commun Signal. 2021 Apr 8;19(1):44 [PMID: 33832488]
  35. Nat Rev Cancer. 2013 May;13(5):357-65 [PMID: 23612461]
  36. Front Oncol. 2018 Oct 30;8:459 [PMID: 30425964]
  37. Nat Rev Endocrinol. 2018 Oct;14(10):576-590 [PMID: 30046148]
  38. Mol Cell Proteomics. 2012 May;11(5):100-7 [PMID: 22389435]
  39. Aging Cell. 2013 Dec;12(6):950-4 [PMID: 23815295]
  40. Neuropharmacology. 2013 Jun;69:96-104 [PMID: 22659085]
  41. Neurotherapeutics. 2013 Apr;10(2):186-98 [PMID: 23385875]
  42. J Hepatol. 2022 Dec;77(6):1631-1641 [PMID: 35988690]
  43. Nat Commun. 2018 Mar 21;9(1):1176 [PMID: 29563510]
  44. Exp Gerontol. 2018 May;105:4-9 [PMID: 29111233]
  45. EMBO J. 2024 Jun;43(12):2337-2367 [PMID: 38649537]

Grants

  1. 856871/European Commission

Word Cloud

Created with Highcharts 10.0.0liverdiseaseHCCCCgeneexpressionprogressionage-associatedsurvivalSUCLG1fattyinflammationcirrhosisageagingage-relatedcanceramongcancerstissuesINTRODUCTION:commonnonalcoholiccharacterizedintrahepaticaccumulationlipidsoftenaccompaniesobesityFattycanevolvepresenceoxidativestressdisablingdeadlydiseaseshepatocellularcarcinomacholangiocarcinomaOldseemsfavoragreementinflammagingtheoryaccordingaccruesCancergeneralincidencemortalitytypesincreaseHowevermoleculardriverstumorsdiffermutatedfrequentlypatientsdifferentagesremainsscarcelyinvestigatedrecentintegrativeanalysismulti-omiclandscapeacrosshealthydemonstratedchangeslinkednumerousbiologicalprocesseslowestfive-yearestimatesdueaggressiveMATERIALSANDMETHODS:studyextractedtopcandidatesabove-mentionedpan-analysesieB2MC1qAtestedqPCRcorrelation48tissuesamplescoveringstageshepatitisnormalRESULTS:reportsignificantdownregulationtowardalsoassociatespoorpatientCONCLUSION:SUCGL1mitochondrialenzymecatalyzesconversionsuccinylCoAsuccinatemighttherapeuticallytargeteddevelopmentlowratesDownregulationAging-AssociatedGeneMarksAggressivenessLiverDisease

Similar Articles

Cited By